AIGEN INVESTMENT MANAGEMENT, LP - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.

Quarter-by-quarter ownership
AIGEN INVESTMENT MANAGEMENT, LP ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$578,219
+93.4%
19,594
+82.3%
0.08%
+102.4%
Q4 2022$298,985
+17.7%
10,751
+231.5%
0.04%
-4.5%
Q2 2021$254,000
+24.5%
3,243
-9.0%
0.04%
+63.0%
Q1 2021$204,000
-55.7%
3,565
-72.3%
0.03%
-54.2%
Q3 2020$461,000
+786.5%
12,877
+331.8%
0.06%
+555.6%
Q4 2019$52,0002,9820.01%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$219,569,00028.65%
ARCH Venture Management, LLC 5,168,749$152,116,00018.54%
Casdin Capital, LLC 1,500,000$44,145,0003.73%
Flagship Pioneering Inc. 2,619,968$77,106,0002.90%
Yiheng Capital Management, L.P. 1,014,684$29,862,0001.71%
SECTORAL ASSET MANAGEMENT INC 202,100$5,948,0001.20%
GILDER GAGNON HOWE & CO LLC 1,956,820$57,589,0001.03%
Artal Group S.A. 600,000$17,658,0000.94%
Temasek Holdings (Private) Ltd 5,369,487$158,024,0020.87%
BRANDYWINE MANAGERS, LLC 9,601$283,0000.69%
View complete list of DENALI THERAPEUTICS INC shareholders